Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ADXS is in the long-term up 2421% in 17 years.
Description: Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. The company?s Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. The company has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. Its products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.97||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-3.44|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-57.87%||ROE||-63.14%||ROI|
|Current Ratio||12.18||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.08|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||38.41 M||Cash From Investing Activities||-340 K||Cash From Operating Activities||-9.73 M||Gross Profit|
|Net Profit||-13.86 M||Operating Profit||-13.84 M||Total Assets||51.69 M||Total Current Assets||48.57 M|
|Total Current Liabilities||3.99 M||Total Debt||30 K||Total Liabilities||4.32 M||Total Revenue|
|High 52 week||7.61||Low 52 week||0.43||Last close||3.31||Last change||0.3%|
|RSI||18.9||Average true range||0.71||Beta||0.51||Volume||687.29 K|
|Simple moving average 20 days||-31.82%||Simple moving average 50 days||-39.52%||Simple moving average 200 days||10.96%|
|Performance Week||-11.26%||Performance Month||-54.27%||Performance Quart||-36.95%||Performance Half||361.78%|
|Performance Year||91.33%||Performance Year-to-date||16.14%||Volatility daily||9.22%||Volatility weekly||20.63%|
|Volatility monthly||42.27%||Volatility yearly||146.44%||Relative Volume||327.71%||Average Volume||1.58 M|
|New High||New Low|
2020-03-03 16:01:10 | Advaxis to Present at the 2020 LD Micro Virtual Conference
2020-02-16 15:03:32 | The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
2020-01-30 09:23:53 | Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings
2020-01-21 08:30:10 | Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering
2020-01-07 08:00:10 | Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
2019-12-22 17:08:44 | Is Advaxis, Inc. ADXS A Good Stock To Buy?
2019-12-20 08:00:00 | Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
2019-12-20 05:04:46 | Did Changing Sentiment Drive Advaxis's NASDAQ:ADXS Share Price Down A Disastrous 99%?
2019-12-04 08:00:00 | Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference
2019-10-24 09:00:00 | Advaxis Announces Business and Pipeline Update
2019-10-10 08:00:00 | Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
2019-10-07 08:00:00 | Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
2019-09-19 06:36:15 | Is This A Catalyst To Buy Advaxis, Inc. NASDAQ:ADXS?
2019-09-09 08:00:00 | Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
2019-08-22 08:00:00 | Advaxis, Inc. Issues Letter to Shareholders
2019-08-12 06:30:00 | BriaCell Appoints Richard J. Berman to Board of Directors
2019-07-23 08:30:00 | Advaxis, Inc. Announces Pricing of $16 Million Public Offering
2019-06-20 04:25:20 | Edited Transcript of ADXS earnings conference call or presentation 11-Jun-19 3:00pm GMT
2019-06-11 09:00:00 | Advaxis, Inc. to Host Earnings Call
2019-06-04 08:00:00 | Advaxis to Host Business Update Conference Call on June 11, 2019
2019-05-25 09:48:01 | What Kind Of Investor Owns Most Of Advaxis, Inc. NASDAQ:ADXS?
2019-05-15 10:25:35 | Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
2019-05-15 08:00:00 | FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
2019-05-07 09:00:00 | Advaxis to Participate in Five Upcoming Industry Conferences
2019-04-18 17:45:09 | Advaxis ADXS Stock Sinks As Market Gains: What You Should Know
2019-04-16 10:54:02 | QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
2019-04-10 08:43:12 | Twist Bioscience TWST Looks Good: Stock Adds 6.5% in Session
2019-04-08 09:30:01 | Is Advaxis ADXS Outperforming Other Medical Stocks This Year?
2019-04-03 16:31:00 | Why Range Resources, Advaxis, and StoneCo Slumped Today
2019-04-03 07:44:00 | Advaxis' stock plummets after public offering prices at deep discount
2019-04-03 07:30:00 | Advaxis Announces Pricing of Its Public Offering of Common Stock
2019-04-02 16:05:00 | Advaxis, Inc. Announces Proposed Public Offering of Common Stock
2019-04-02 09:44:01 | Advaxis Up on Positive Early-Stage Immunotherapy Study Data
2019-04-01 16:31:00 | Why Wynn Resorts, Advaxis, and Roku Jumped Today